The new Siegfried plant will offer contract manufacturing for APIs, intermediates and finished oral drugs
Singapore: Switzerland-based contract manufacturing organization (CMO), Siegfried Holdings, has started the construction of its new pharma manufacturing plant in Nantong, China.
The new plant, which would be the company's first facility in China, will have a capacity of 300 cubic meters. Siegfried will offer contract manufacturing for APIs, intermediates and finished oral drugs, along with other development services at its new plant.
Presently, Siegfried has plants in Switzerland, Malta and the US.
